Breast Cancer Screening Market by Technology, Product, End User

List of Tables

The Breast Cancer Screening Market is projected to reach USD 7.90 billion by 2030 from USD 4.73 billion in 2022, at a CAGR of 6.61% during the forecast period.

Global Breast Cancer Screening Market

KEY MARKET STATISTICS
Base Year Value [2022]	USD 4.73 billion
Estimated Year Value [2023]	USD 5.01 billion
Forecast Year Value [2030]	USD 7.90 billion
CAGR (%)	6.61%

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Breast Cancer Screening Market.

Based on Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging. The Non-ionizing Breast Imaging Technologies is projected to witness significant market share during forecast period.

Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services. The Breast Imaging Systems is projected to witness significant market share during forecast period.

Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics. The Diagnostic Imaging Centers is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Breast Cancer Screening Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Breast Cancer Screening Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Breast Cancer Screening Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca plc, Bayer AG, Becton, Dickinson and Company, Carestream Health, Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GlaxoSmithKline plc, Hologic, Inc., Koning Health, Koninklijke Philips N.V., Myriad Genetics, Inc., NanoString Technologies, Inc., NIRAMAI Health Analytix Private Limited, Novartis AG, Oncocyte Corporation, OncoStem Diagnostics Pvt. Ltd, Pfizer Inc., Prelude Corporation, Quest Diagnostics Incorporated, Siemens Healthineers AG, Syantra Inc., and Vayyar Imaging, Ltd..

The report offers valuable insights on the following aspects:

1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.

2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.

3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.

4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.

5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast for the Breast Cancer Screening Market?

2. Which products, segments, applications, and areas hold the highest investment potential in the Breast Cancer Screening Market?

3. What is the competitive strategic window for identifying opportunities in the Breast Cancer Screening Market?

4. What are the latest technology trends and regulatory frameworks in the Breast Cancer Screening Market?

5. What is the market share of the leading vendors in the Breast Cancer Screening Market?

6. Which modes and strategic moves are suitable for entering the Breast Cancer Screening Market?

Product Code: MRR-521BAA36EB69

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Breast Cancer Screening Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing cases of cancer in women globally
  - 5.1.1.2. Government health campaign to raise disease awareness
  - 5.1.1.3. Significant adoption of MRI techniques for screening and monitoring.
- 5.1.2. Restraints
  - 5.1.2.1. Breast cancer screening device recalls
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of AI-supported 3D mammogram screening for cancer screening
  - 5.1.3.2. Adoption of advanced Immunotherapy
- 5.1.4. Challenges
  - 5.1.4.1. Potential risk of false results
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Breast Cancer Screening Market, by Technology

6.1. Introduction
6.2. Ionizing Breast Imaging Technologies
- 6.3.1. 3D Breast Tomosynthesis
- 6.3.2. Analog Mammography
- 6.3.3. Cone-Beam Computed Tomography (CBCT)
- 6.3.4. Contrast-Enhanced Mammography (CEM)
- 6.3.5. Full-Field Digital Mammography (FFDM)
- 6.3.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
- 6.3.7. Positron Emission Mammography (PEM)
- 6.3.8. Positron Emission Tomography and Computed Tomography (PET-CT)
6.3. Non-ionizing Breast Imaging Technologies
- 6.4.1. Automated Whole-Breast Ultrasound (AWBU)
- 6.4.2. Breast MRI
- 6.4.3. Breast Thermography
- 6.4.4. Breast Ultrasound
- 6.4.5. Electric Impedance Tomography
- 6.4.6. Optical Imaging

7. Breast Cancer Screening Market, by Product

7.1. Introduction
7.2. Accessories
7.3. Breast Imaging Systems
7.4. Software & Services

8. Breast Cancer Screening Market, by End User

8.1. Introduction
8.2. Breast Care Centers
8.3. Diagnostic Imaging Centers
8.4. Hospitals & Clinics

9. Americas Breast Cancer Screening Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Breast Cancer Screening Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Breast Cancer Screening Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. AstraZeneca plc
- 13.1.2. Bayer AG
- 13.1.3. Becton, Dickinson and Company
- 13.1.4. Carestream Health, Inc.
- 13.1.5. Danaher Corporation
- 13.1.6. Exact Sciences Corporation
- 13.1.7. F. Hoffmann-La Roche Ltd
- 13.1.8. Fujifilm Holdings Corporation
- 13.1.9. GE HealthCare Technologies Inc.
- 13.1.10. GlaxoSmithKline plc
- 13.1.11. Hologic, Inc.
- 13.1.12. Koning Health
- 13.1.13. Koninklijke Philips N.V.
- 13.1.14. Myriad Genetics, Inc.
- 13.1.15. NanoString Technologies, Inc.
- 13.1.16. NIRAMAI Health Analytix Private Limited
- 13.1.17. Novartis AG
- 13.1.18. Oncocyte Corporation
- 13.1.19. OncoStem Diagnostics Pvt. Ltd
- 13.1.20. Pfizer Inc.
- 13.1.21. Prelude Corporation
- 13.1.22. Quest Diagnostics Incorporated
- 13.1.23. Siemens Healthineers AG
- 13.1.24. Syantra Inc.
- 13.1.25. Vayyar Imaging, Ltd.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing